Liang Han - Concepedia

Author

Liang Han

Tianjin Medical University Cancer Institute and Hospital ORCID

Also Known As

H Liang, H. Liang, Han Liang, Han, Liang, Hongyun Liang, Huijie Liang, Huishi Liang, L Han, L. Han, Li, Z. X.

189

Publications

2.5K

Citations

H-Index

Concepts

All Affiliations

Tianjin Medical University Cancer Institute and Hospital Jilin University Harbin Medical University Peking University Cancer Hospital Peking University

About

Liang Han is an author at Tianjin Medical University Cancer Institute and Hospital specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	10	10	987
2	Health Sciences	4	4	464
3	Gastroenterology	2	2	48
4	Cell Biology	1	1	14
5	Geriatrics	1	1	21

Liang Han

Publications

Citations

H-Index

Page 1

	Year	Citations
Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer Ying Cheng, Liang Han, Lin Wu, JAMA	2022	415
Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial Xiaotian Zhang, Liang Han, Ziyu Li, The Lancet Oncology D2 GastrectomySurgical OncologyEsophageal CancerGastrointestinal OncologyMedicine	2021	414
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial Shun Lü, Lin Wu, Hong Jian, The Lancet Oncology OncologyFirst Interim ResultsBevacizumab Biosimilar Ibi305Clinical TrialsPathology	2022	227
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial Shun Lü, Lin Wu, Hong Jian, The Lancet Respiratory Medicine OncologyDisease ProgressionSecond Interim AnalysisMetronomic TherapyClinical Trials	2023	181
Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non–Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01) Zhijie Wang, Lin Wu, Baolan Li, Journal of Clinical Oncology	2022	161
JAK2/STAT3 targeted therapy suppresses tumor invasion via disruption of the EGFRvIII/JAK2/STAT3 axis and associated focal adhesion in EGFRvIII-expressing glioblastoma Qi Zheng, Liang Han, Yan Dong, Neuro-Oncology	2014	93
Neoadjuvant PARPi or chemotherapy in ovarian cancer informs targeting effector Treg cells for homologous-recombination-deficient tumors Yikai Luo, Yu Xia, Dan Liu, Cell	2024	69
A novel nomogram individually predicting disease‐specific survival after D2 gastrectomy for advanced gastric cancer Wei Wang, Zhe Sun, Jing‐Yu Deng, Cancer Communications	2018	66
Molecular Subtyping and Prognostic Assessment Based on Tumor Mutation Burden in Patients with Lung Adenocarcinomas Changzheng Wang, Liang Han, Cong Lin, International Journal of Molecular Sciences	2019	41
International consensus on natural orifice specimen extraction surgery (NOSES) for gastric cancer (2019) Xu Guan, Zheng Liu, Amjad Parvaiz, Gastroenterology report Surgical OncologyMedicineInternational ConsensusGastroenterologyPathology	2019	38

Page 1